PUBLISHER: The Business Research Company | PRODUCT CODE: 1948625
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948625
Virtual biopsy is a non-invasive diagnostic method that leverages advanced imaging technologies and computer algorithms to analyze tissues for signs of disease. Its primary goal is to identify abnormalities, such as tumors or infections, without the need for traditional tissue sampling, minimizing risks and recovery time for patients. This technique is safer, faster, and less painful compared to conventional biopsies.
The main therapeutic areas targeted by virtual biopsy include oncology, neurology, cardiology, ophthalmology, endocrinology, gastroenterology, and other related conditions. Oncological disorders involve diseases characterized by the uncontrolled growth and spread of abnormal cells, commonly known as cancer, which can affect various organs and tissues. Virtual biopsy is used for detecting a wide range of cancers, including solid tumors, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. The imaging technologies utilized in virtual biopsy include magnetic resonance imaging (MRI), computed tomography (CT), X-ray, ultrasound, among others, and are employed by end users such as hospitals, clinics, research institutes, diagnostic centers, and more.
Tariffs are impacting the virtual biopsy market by increasing the cost of importing advanced imaging equipment, software platforms, and diagnostic tools. Segments such as magnetic resonance imaging and computed tomography devices are most impacted, particularly in Asia-Pacific regions including China and India. While tariffs have raised production and operational costs, they also encourage local manufacturing, foster innovation in cost-effective imaging solutions, and promote the development of domestic diagnostic technology capabilities.
The virtual biopsy market research report is one of a series of new reports from The Business Research Company that provides virtual biopsy market statistics, including virtual biopsy industry global market size, regional shares, competitors with a virtual biopsy market share, detailed virtual biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the virtual biopsy industry. This virtual biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The virtual biopsy market size has grown rapidly in recent years. It will grow from $0.71 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to reliance on traditional biopsy procedures, limited imaging technology capabilities, increasing prevalence of chronic diseases, growing hospital and diagnostic infrastructure, rising demand for accurate cancer diagnostics.
The virtual biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.23 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancements in imaging algorithms and ai analytics, expansion of oncology and neurological diagnostic applications, increasing adoption in cardiovascular and ophthalmological disorders, integration with personalized medicine approaches, rising investment in research institutes and diagnostic centers. Major trends in the forecast period include increased adoption of non-invasive diagnostic procedures, rising demand for early disease detection, integration of advanced imaging with predictive analytics, expansion of virtual biopsy applications across multiple therapeutic areas, growing focus on patient comfort and reduced recovery time.
The rising prevalence of oncological disorders is expected to drive the growth of the virtual biopsy market in the coming years. Oncological disorders are health conditions related to cancer, characterized by the abnormal growth and spread of cells in the body. The increasing prevalence of these disorders is largely attributed to lifestyle factors such as poor diet, physical inactivity, tobacco use, and greater exposure to environmental pollutants. Virtual biopsy enhances the diagnosis and monitoring of oncological disorders by providing non-invasive, real-time imaging insights, reducing reliance on traditional tissue biopsies while improving accuracy and patient safety. For example, in January 2023, Rock Health, a U.S.-based digital health research firm, reported that 1,958,310 new cancer cases were projected in the U.S. for 2023, up from approximately 1.9 million cases in 2022. Therefore, the rising prevalence of oncological disorders is driving the virtual biopsy market.
The growing demand for telemedicine is also expected to propel the virtual biopsy market. Telemedicine refers to the remote delivery of healthcare services using digital communication technologies, including video conferencing, mobile applications, and telecommunication networks. The increasing adoption of telemedicine is driven by improved healthcare accessibility, cost efficiency, and advancements in digital health technologies. Virtual biopsy supports telemedicine by enabling remote, non-invasive tissue assessment through advanced imaging and AI-powered analysis, allowing clinicians to monitor and diagnose patients without in-person visits, thereby enhancing accessibility and continuity of care. For instance, in July 2023, Harmony Healthcare IT, a US-based data management firm, reported that 62% of Americans had used telehealth services for medical needs, with over three-quarters (77%) viewing it as the future of healthcare. Therefore, the rising demand for telemedicine is driving the growth of the virtual biopsy market.
Major companies in the virtual biopsy market are focusing on developing technologically advanced solutions and obtaining regulatory approvals, such as magnetic resonance spectroscopy (MRS) platforms, to enhance non-invasive diagnostic accuracy and provide real-time analysis for early disease detection and personalized treatment. Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that enables virtual biopsy by providing detailed molecular information of tissues, allowing accurate, real-time disease detection and monitoring without invasive procedures. For example, in November 2023, BrainSpec Inc., a US-based healthtech company, received approval from the U.S. Food and Drug Administration (FDA) for its AI-driven BrainSpec platform. This technology applies advanced artificial intelligence analysis to MR spectroscopy data to measure brain metabolites such as 2-hydroxyglutarate, facilitating non-invasive virtual biopsies for conditions including gliomas, Alzheimer's disease, and multiple sclerosis. The system integrates seamlessly with standard MRI scanners, automates data processing, delivers results within minutes, and leverages a reference database of brain chemistry to improve diagnostic accuracy.
Major companies operating in the virtual biopsy market are Siemens Healthineers AG, GE Healthcare, Canon Medical Systems, Philips Healthcare, Fujifilm Healthcare, Esaote SpA, Samsung Medison, Perspectum Ltd, QUIBIM SL, ImageBiopsy Lab GmbH, Deep Bio Inc, BrainSpec Inc, Oncoustics Inc, AI Metrics LLC, Zebra Medical Vision, Arterys Inc, Aidoc Medical, Viz ai, Subtle Medical, Gleamer AI
North America was the largest region in the virtual biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the virtual biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The virtual biopsy market consists of revenues earned by entities by providing services such as imaging diagnostics, artificial intelligence (AI)-based interpretation, biomarker testing, telemedicine services, and three-dimensional (3D) tissue modeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The virtual biopsy market also includes sales of biopsy needle systems, artificial intelligence (AI)-based diagnostic tools, endoscopic systems, and photoacoustic imaging devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Virtual Biopsy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses virtual biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for virtual biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The virtual biopsy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.